RT Journal Article SR Electronic T1 Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 1650 OP 1657 DO 10.3899/jrheum.121515 VO 40 IS 10 A1 Bernard Combe A1 Nathalie Rincheval A1 Joelle Benessiano A1 Francis Berenbaum A1 Alain Cantagrel A1 Jean-Pierre Daurès A1 Maxime Dougados A1 Patrice Fardellone A1 Bruno Fautrel A1 Rene M. Flipo A1 Philippe Goupille A1 Francis Guillemin A1 Xavier Le Loët A1 Isabelle Logeart A1 Xavier Mariette A1 Olivier Meyer A1 Philippe Ravaud A1 Alain Saraux A1 Thierry Schaeverbeke A1 Jean Sibilia YR 2013 UL http://www.jrheum.org/content/40/10/1650.abstract AB Objective. To report the 5-year outcome of a large prospective cohort of patients with very early rheumatoid arthritis (RA), and to identify factors predictive of outcome. Methods. Patients were recruited if they had early arthritis of < 6 months’ duration, had a high probability of developing RA, and had never been prescribed disease-modifying antirheumatic drugs (DMARD) or steroids. Logistic regression analysis was used to determine factors that predict outcome. Results. We included 813 patients from December 2002 to April 2005. Age was 48.1 ± 12.6 years, delay before referral 103.1 ± 52.4 days, 28-joint Disease Activity Score (DAS28) 5.1 ± 1.3, Health Assessment Questionnaire (HAQ) 1.0 ± 0.7; 45.8% and 38.7% had rheumatoid factor or antibodies to cyclic citrullinated peptide (anti-CCP), respectively; 22% had hand or foot erosions; 78.5% fulfilled the American College of Rheumatology/European League Against Rheumatism criteria for RA at baseline and 93.8% during followup. At 5 years, 573 patients were evaluated. The outcome was mild for most patients: disease activity (median DAS28 = 2.5) and HAQ disability (median 0.3) were well controlled over time; 50.6% achieved DAS28 remission and 64.7% low disease activity. Radiographic progression was low (2.9 Sharp unit/year) and only a few patients required joint surgery. Nevertheless, some patients developed new comorbidities. During the 5 years, 82.7% of patients had received at least 1 DMARD (methotrexate, 65.9%), 18.3% a biological DMARD, and about 60% prednisone at least once. Anti-CCP was the best predictor of remaining in the cohort for 5 years, of prescription of synthetic or biologic DMARD, and of radiographic progression. Conclusion. The 5-year outcome of an early RA cohort in the 2000s was described. Anti-CCP was a robust predictor of outcome. The generally good 5-year outcome could be related to early referral and early effective treatment, key processes in the management of early RA in daily practice.